Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.33 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.33 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.32 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 4/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992203 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL28506360 | 0.98 | CYP1A2 (0.47) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| SCHEMBL3095991 | 0.96 | CYP1A2 (0.48) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL248532 | 0.91 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL28296907 | 0.89 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Ethane SCHEMBL2545448 | 0.89 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| SCHEMBL301678 | 0.89 | — | — | |
| Ethane SCHEMBL8026831 | 0.86 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Carbimide SCHEMBL8927383 | 0.86 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Iodomethane SCHEMBL7521844 | 0.84 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737444-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-04-22 | — | — | US | disclosed |
| CN-114787139-B | Methods and intermediates for preparing MCL1 inhibitors | 吉利德科学公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4484435-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4065567-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240109851-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-114917352-B | Drug-loaded disc particles with functions of adhering and regulating macrophages, and preparation method and application thereof | 西南交通大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-1993011764-A1 | FLUORENYL DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCIOS NOVA INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5164509-A | BENZODIAZOLO ANALOGS | E. R. SQUIBB & SONS, INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0501797-A1 | Pyranyl cyanoguanidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| EP-0500170-A2 | Cyclic hexapeptides having antibiotic activity | MERCK & CO. INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5140031-A | Pyranyl cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| CN-1061961-A | 1,2-indane and quinoline | SQUIBB & SONS INC (US) | 1992-06-17 | — | — | CN | disclosed |
| EP-0488616-A1 | Indane and quinoline derivatives | E.R. SQUIBB & SONS, INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| EP-0488107-A2 | Tricyclic benzodiazole analogs and their use in the treatment of cardiovascular disorders | E.R. SQUIBB & SONS, INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| US-5006523-A | Antiarrhythmic agents: aryl cyanoguanidine potassium channel blockers | E. R. SQUIBB & SONS, INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0401010-A2 | Pyranyl cyanoguanidine derivatives | E.R. Squibb & Sons, Inc. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | MAOA 4473/4885MAOB 4198/4885HRH2 4750/4885 |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | MAOA 4473/4885MAOB 4198/4885HRH2 4750/4885 |
| US-12281109-B2 | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes | HDAC3, HDAC1, HDAC2 | MAOA 869/4885MAOB 768/4885HRH2 1208/4885 |
| US-20240109851-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | MAOA 4473/4885MAOB 4198/4885HRH2 4750/4885 |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | MAOA 4473/4885MAOB 4198/4885HRH2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.